VOYA Investment Management
EVLO

VOYA Investment Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

VOYA Investment Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-600
Closed -$41K – 2943
2022
Q1 		$41K Hold
600
– – ﹤0.01% 2612
2021
Q4 		$73K Sell
600
-6
-1% -$1.01K ﹤0.01% 2710
2021
Q3 		$85K Hold
606
– – ﹤0.01% 2771
2021
Q2 		$167K Buy
+606
New +$153K ﹤0.01% 2656

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VOYA Investment Management's EVLO Position: Q2 2022 in Review

VOYA Investment Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2022, closing a stake of 600 shares — an estimated $41K sold.

VOYA Investment Management first reported a position in EVLO in Q2 2021 and held it in 4 quarters. The position peaked at $167K in Q2 2021. 46 funds tracked by Wall St. Rank hold EVLO as of Q2 2022.

  • VOYA Investment Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • VOYA Investment Management sold 600 Evelo Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $41K.
  • VOYA Investment Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • VOYA Investment Management's Evelo Biosciences, Inc. Common Stock position peaked at $167K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2022.

Based on VOYA Investment Management's 13F filing for Q2 2022, filed 15 Aug 2022.